Hepatitis B Virus Core Antibody, IgM
Also known as: HBCABM
Use
The Hepatitis B Virus Core Antibody, IgM test is utilized to determine the presence of IgM antibodies against the core antigen of the Hepatitis B virus. This is typically an indication of acute or recent infection with Hepatitis B, as IgM antibodies are produced early in the infection cycle. It is especially useful in diagnosing acute hepatitis B infection when used as part of an acute hepatitis panel including HAV IgM, HBV surface antigen, and HCV antibody. A positive result may indicate a recent Hepatitis B infection and suggests that the patient could be in a potentially infectious state.
Special Instructions
Not provided.
Limitations
The test has specific limitations in that it should not be used for screening blood donors or for the associated reentry protocols. It is also not suitable for screening human cells, tissues, and cellular- and tissue-based products (HCT/P). Special attention should be given to the stability of the specimen post-collection to ensure accurate results.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
Hepatitis B Core Antibody, IgM
Antibody
LOINC Codes
- 24113-3 - HBV core IgM SerPl Ql IA
- 24113-3 - HBV core IgM SerPl Ql IA
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP standard transport tube, also acceptable: K2EDTA plasma
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated transport is required.
Causes for Rejection
Heparinized plasma. Specimens containing particulate material. Heat-inactivated, severely hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | Indefinitely (avoid repeated freeze/thaw cycles) |
Other tests from different labs that may be relevant